Contents

Search

crizanlizumab

Indications: - prevention of sickle cell painful crises * may be used in conjunction with hydroxyurea Dosage: - 2.5-5.0 mg/kg every 4 weeks Mechanism of action: - inhibits P-selectin

Interactions

drug adverse effects of pharmaceutical monoclonal antibodies

General

pharmaceutical monoclonal antibody

References

  1. Ataga KI, Kutlar A, Kanter J et al. Crizanlizumab for the prevention of pain crises in sickle cell disease. N Engl J Med 2016 Dec 3; PMID: 2795970